Key result
Corneal application of the renin inhibitor enalkiren significantly decreased intraocular pressure for at least 60 minutes in monkeys and 90 minutes in rabbits without affecting systemic blood pressure.
Why the study?
Does corneal application of enalkiren lower intraocular pressure in rabbits and monkeys?
Does corneal application of enalkiren lower intraocular pressure in rabbits and monkeys?
Topical application of the renin inhibitor enalkiren lowers intraocular pressure in animal models without systemic cardiovascular effects, suggesting a role for the renin-angiotensin system in IOP modulation.
Does not support clinical use; leaves open human translation of topical renin inhibition for IOP control.
Corneal application of enalkiren (ABBOTT-64662), [N-(3-amino-3-methyl-1- oxobutyl)-4-methoxy-L-phenylalanyl]-N-[1S,2R,3S)-1-(cyclohexylmethyl+ ++)-2,3- dihydroxy-5-methylhexyl]-L-histidinamide], a renin inhibitor compound, lowered intraocular pressure (IOP) in unanesthetized rabbits and anesthetized monkeys. IOP was significantly decreased for at least 60 minutes after administration of a 0.3% solution of enalkiren in monkeys and for at least 90 minutes after the administration of 0.1% and 0.3% solutions in rabbits. Enalkiren did not affect systemic blood pressure or heart rate in anesthetized monkeys after topical application to the cornea. The IOP lowering activity of enalkiren suggests a potential functional role for the renin angiotensin system in the modulation of IOP.
No takes yet. Share an insight, caveat, or question.
Giardina et al. (1990) studied Intraocular pressure. Enalkiren (ABBOTT-64662) was evaluated on Intraocular pressure (IOP). Corneal application of the renin inhibitor enalkiren significantly decreased intraocular pressure for at least 60 minutes in monkeys and 90 minutes in rabbits without affecting systemic blood pressure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: